Phosphotyrosine phosphatase inhibitors or phosphotyrosine kinase

Details Phosphotyrosine phosphatase inhibitors or phosphotyrosine kinase Phosphotyrosine phosphatase inhibitors or phosphotyrosine kinase

1995-06-05

1999-03-02

Achutamurthy, Ponnathapura

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heavy metal containing doai

556 1, 556 42, 556 44, 4241781, 4241791, 4241811, 435184, 435244, A01N 5502, A61K 39395, C07F 5300

Patent

active

058772103

ABSTRACT:
A method of inhibiting the proliferation of B cells by using inhibitors of phosphotyrosine phosphatase can be used to regulate the immune response and to treat diseases such as leukemias or lymphomas marked by malignant proliferation of B cells or T cells. Antitumor activity is seen in vivo against tumors and against tumor cell lines. The use of such inhibitors can be combined with radiation, which produces a synergistic effect. Several types of inhibitors can be used, including: (1) compounds comprising a metal coordinate-covalently bound to an organic moiety that can form a five- or six-membered ring, in which the metal is preferably vanadium (IV); (2) compounds in which vanadium (IV) is coordinate-covalently bound to an organic moiety such as a hydroxamate, .alpha.-hydroxypyridinone, .alpha.-hydroxypyrone, .alpha.-amino acid, hydroxycarbonyl, or thiohydroxamate; (3) coordinate-covalent complexes of vanadyl and cysteine or a derivative thereof; (4) nonhydrolyzable phosphotyrosine phosphatase analogues; (5) dephostatin; (6) 4-(fluoromethyl)phenyl phosphate and esterified derivatives; and (7) coordinate-covalent metal-organic compounds containing at least one oxo or peroxo ligand bound to the metal, in which the metal is preferably vanadium (V), molybdenum (VI), or tungsten (VI). Methods of stimulating signaling in T cells and conjugates of a modulator of phosphotyrosine metabolism with a specific binding partner for a B cell surface antigen are also disclosed.

REFERENCES:
patent: 5023358 (1991-06-01), Lazaro et al.
patent: 5175001 (1992-12-01), Lazaro et al.
G.J.V. Nossal, "Cellular Mechanisms of Immunologic Tolerance", Annu. Rev. Immunol. 1:33-62 (1983).
F.M. Uckun & J.A. Ledbetter, "Immunobiologic Differences Between Normal and Leukemic Human Cell Precursors", Proc.Natl.Acad.Sci.USA 85: 8603-8607 (1988).
T.R. Burke et al., "Preparation of Fluoro-and Hydroxy-4-(Phosphonomethyl)-D,L-Phenylalanine Suitably Protected for Solid-Phase Synthesis of Peptides Containing Hydrolytically Stable Analogues of O-Phosphotyrosine", J.Org.Chem. 48: 1336-1340 (1993).
D.B.A. de Bont et al., "Solid-Phase Synthesis of O-Phosphorothioylserine-and Threonine-Containing Peptides as Well as of O-Phosphoserine-and-Theronine-Containing Peptides", J. Org. Chem. 58: 1309-1317 (1993).
K. Guan et al., "A Tyr/Ser Protein Phosphatase Encoded by Vaccinia Virus", Nature 350: 359-362 (1991).
D. Dailey et al., "Novel Yeast Protein Kinae (YPK1 Gene Product) Is a 40-Kilodalton Phosphotyrosyl Protein Associated with Protein-Tyrosine Kinase Activity", Mol. Cell. Biol. 10: 6244-6256 (1990).
M. Imoto et al., "Dephostatin, a Novel Protein Tyrosine Phosphatase Inhibitor Produced by Streptomyces. I. Taxonomy, Isolation, and Characterization", J. Antibiotics 46: 1342-1346 (1993).
J. H. McNeill et al., "Bis(maltolato) oxovanadium (IV) Is a Potent Insulin Mimic", J.Med.Chem. 35: 1489-1491 (1992).
R.R. Bartlett et al., Leflunomide (HWA 486), a Novel Immunomodulating Compound for the Treatment of Autoimmune Disorders and Reactions Leading to Transplantation Rejection, Agents & Actions 32: 10-21 (1991).
J.K. Myers & T.S. Widlanski, Mechanism-Based Inactivation of Prostatic Acid Phosphatase, Science 262: 1451-1453 (1993).
L.B. Justement et al., "Regulation of B Cell Antigen Receptor Signal Transduction and Phosphorylation of CD45", Science 252: 1839-1842, (1991).
M.R. Gold et al, "Stimulation of Protein Tyrosine Phosphorylation by the B-Lymphocyte Antigen Receptor", Nature 345: 810-843 (1990).
M.C. Cam et al., "In Vivo Antidiabetic Actions of Naglivan, An Organic Vanadyl Compound in Streptozotocin-Induced Diabetes", Diabetes Res. & Clin. Pract. 20: 111-121 (1993).
A.L. Burkhardt et al., "Anti-Immunoglobulin Stimulation of B Lymphocytes Activates src-Related Protein-Tyrosine Kinases," Proc. Natl. Acad. Sci. USA 88: 7410-7414 (1991).
F.M. Uckun et al., "Tyrosine Phosphorylation Is a Mandatory Proximal Step in Radiation-Induced Activation of the Protein Kinase C Signaling Pathway in Human B-Lymphocyte Precursors," Proc. Natl. Acad. Sci. USA 90: 252-256 (1993).
C.P. Stewart & A.L. Prote, "Electron Paramagnetic Resonance Spectra of Some Oxovanadium (IV) Chelates," J. Chem. Soc. Dalton Trans. 1661-1666 (1972).
X.-R. Yao & D.W. Scott, "Expression of Protein Tyrosine Kinases in the Ig Complex of Anti-.mu.-Sensitive and Anti-.mu.-Resistant B-Cell Lymphomas: Role of the p55.sup.blk Kinase in Signalling Growth Arrest and Apoptosis," Immunol. Rev. 132: 163-186 (1993).
X.-R. Yao & D.W. Scott, "Antisense Oligodeoxynucleotidase to the blk Tyrosine Kinase Prevent Anti-.mu.-Chain-Mediated Growth Inhibition and Apoptosis in a B-Cell Lymphoma," Proc. Natl. Acad. Sci. USA 90: 7946-7950 (1993).
F.M. Uckun et al., "Ionizing Radiation Stimulates Unidentified Tyrosine-Specific Protein Kinases in Human B-Lymphocyte Precursors, Triggering Apoptosis and Clonogenic Cell Death," Proc. Natl. Acad. Sci. USA 89: 9005-9009 (1992).
P.J.L. Lane et al., "The Role of Tyrosine Phosphorylation in Signal Transduction Through Surface Ig in Human B Cells," J. Immunol. 146: 715-722 (1991).
F.M. Uckun et al., "Use of Novel Colony Assay to Evaluate the Cytotoxicity of an Immunotoxin Containing Pokeweed Antiviral Protein Against Blast Progenitor Cells Freshly Obtained from Patients with Common B-Lineage Acute Lymphoblastic Leukemia," J. Exp. Med. 163; 347-368 (1986).
M.A. Campbell & B.M. Sefton, "Protein Tyrosine Phosphorylation is Induced in Murine B Lymphocytes in Response to Stimulation with Anti-Immunoglobulin," EMBO J. 9: 2125-2131 (1990).
Abstract, Meeting of the Oxygen Society, Charleston, South Carolina, on Nov. 12-17, 1993, by G.L. Schieven, et al., entitled "Identification of Reactive Oxygen Intermediate Responsive Tyrosine Kinases in Lymphocytes".
Abstract, Ninth International Symposium on Cellular Endocrinology: "Cell Signalling and the Molecular Stress Response", Lake Placid, New York, Sep. 23-26, 1993, by G.L. Schieven et al., entitled Identification of Reactive Oxygen Intermediate Responsive Tyrosine Kinases in Lymphocytes.
A. Shaver et al., "Insulin-Mimetic Peroxovanadium Complexes: Preparation and Structure of Potassium Oxodiperoxo H.sub.4 NCOO)!.2H.sub.2 O, and Potassium Oxidiperoxo (OHC.sub.5 H.sub.3 NCOO)!.3H.sub.2 O, and Their Reactions with Cysteine," Inorg. Chem. 32: 3109-3113 (1993).
J.P. Secrist et al., "Stimulatory Effects of the Protein Tyrosine Phosphatase Inhibitor, Pervanadate, on T-Cell Activation Events," J. Biol. Chem. 268:5886-5893 (1993).
F.M. Uckun et al., "Biotherapy of B-Cell Precursor Leukemia by Targeting Genistein to CD19-Associated Tyrosine Kinases," Science 267: 886-891 (1995).

Affiliated with

Also associated with

Rating

Phosphotyrosine phosphatase inhibitors or phosphotyrosine kinase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Phosphotyrosine phosphatase inhibitors or phosphotyrosine kinase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphotyrosine phosphatase inhibitors or phosphotyrosine kinase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-423371